Both are in the Medical Products Industry for diabetes.
Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms.
For the recent correction, PODD has a -45% deep base while DXCM has a -58%.
PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since.
So, it really depends on your strategy. If you are looking for aplha then NASDAQ:DXCM is the stock for you but, if you prefer low beta then NASDAQ:PODD is better.